FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年11月6日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 和鉑醫藥控股有限公司 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 20,000,000,000 | USD | | 0.000025 USD | | 500,000 | | 增加 / 減少 (-) | | | 0 | | USD | | 0 | | 本月底結存 | | 20,000,000,000 | USD | | 0.000025 USD | | 500,000 | 本月底法定/註冊股本總額： USD 500,000 FF301 第 1 ...

Group 1: AI Infrastructure Challenges - Microsoft CEO Nadella and OpenAI's Sam discussed that the main bottleneck for AI computing power expansion is not chip shortages but rather electricity resources and related infrastructure [1] - North American data centers have high electricity consumption and require higher voltage substations (230/345kV), while overseas equipment manufacturers face tight capacity for high-voltage transformer equipment [1] - Wanlian Securities reported that China's power equipment products have technological and cost advantages, with increasing competitiveness and export potential in overseas markets [1] Group 2: Company Developments - BYD announced that as of October, its total installed capacity for new energy vehicle power batteries and energy storage batteries exceeds 230 GWh [4] - Heptagon Pharmaceuticals signed an evaluation and licensing agreement with UMOJA BIOPHARMA to advance the development of multiple in vivo CAR-T cell products [5] - Easy Dazhong entered a cooperation agreement with Bridge Mining for integrated coal mining, logistics, and marketing services, with a minimum monthly supply of 100,000 tons of coal products expected to start operations in December 2025 [6][7] Group 3: Financial Performance - Sunac China announced that its offshore debt restructuring plan was approved by the High Court, with the plan set to take effect on November 5, 2025 [8] - Tianli International Holdings expects to record a profit of approximately RMB 650 million for the year ending August 31, 2025, representing a year-on-year growth of about 17% [9] - Cathay Pacific plans to repurchase approximately 643 million shares from Qatar Airways at a price of HKD 10.8374 per share, reflecting a discount of about 3.9% from the last trading price [10] Group 4: Market Trends - Hon Hai Precision reported an 11.3% increase in October revenue, driven by strong demand for AI accelerators, with expectations of a 15% sales growth for the quarter ending December [11] - Yujian plans to place 16.66 million shares at a discount of approximately 10.3%, raising about HKD 771 million [12] - Wangshan Wangshui-B saw a significant increase in dark market trading, with shares rising over 130% to HKD 85 from an IPO price of HKD 33.37 [13] Group 5: New Listings - Several companies, including WeRide, Joyson Electronics, and Pony.ai, are set to list on the Hong Kong Stock Exchange, with share prices set at HKD 27.1, HKD 22, and HKD 139 respectively [14]

Group 1 - The actual controller of Weining Health, Zhou Wei, was sentenced to one and a half years in prison and fined 200,000 yuan, while the subsidiary Shenzhen Weining Zhongtian was fined 800,000 yuan [1] - Weining Health claims that this incident will not have a significant adverse impact on its operations, but the involvement of the actual controller raises concerns about corporate governance and reputation [1] - The case highlights weaknesses in internal control and compliance, prompting investors to be cautious about potential governance issues and ripple effects [1] Group 2 - Northeast Pharmaceutical was ordered to pay 16.45 million yuan in damages due to a contract dispute, with the court rejecting other claims for compensation [2] - This ruling represents a substantial financial loss for Northeast Pharmaceutical and exposes vulnerabilities in its internal control and contract management [2] Group 3 - Novo Nordisk's semaglutide sales reached $25.462 billion in the first three quarters, a 24% increase year-on-year, maintaining a slight lead over Eli Lilly's tirzepatide, which generated $24.837 billion in sales [3] - The competition between semaglutide and tirzepatide reflects the significant market demand and innovation in the metabolic disease sector, with both products driving technological advancements and market expansion [3] Group 4 - HAPO Pharma's subsidiary Nona Bio has entered into an evaluation and licensing agreement with Umoja Biopharma to advance multiple CAR-T cell product developments [4] - This partnership enhances the strategic collaboration established in September 2024 and validates the value of HAPO Pharma's core platform technology [4] - The agreement allows HAPO Pharma to alleviate funding pressures by having the partner bear the high costs of subsequent research and commercialization, showcasing the commercial potential of its cutting-edge technology platforms [4]

Major Events - Wangshan Wangshui-B (02630) has set its share price at HKD 33.37, with the Hong Kong public offering receiving a subscription rate of 6,238.42 times [1] - WeRide-W (00800) achieved a subscription rate of 73.44 times for its Hong Kong public offering, raising approximately HKD 2.264 billion from the global offering [1] - Pony.ai-W (02026) had a subscription rate of 15.88 times for its Hong Kong public offering, with a share price set at HKD 139 [1] - Joyson Electronics (00699) saw a subscription rate of 147.67 times for its Hong Kong public offering, with an expected listing date of November 6 [1] - Standard Chartered Group (02888) plans to issue USD 1 billion in fixed-rate reset perpetual subordinated or convertible securities [1] - Crystal Tech Holdings (02228) subsidiary AILUX announced a strategic partnership with Eli Lilly to enhance AI-driven bispecific antibody development [1] - Giant Star Legend (06683) signed a sales contract exceeding HKD 100 million for quadruped robots, accelerating the integration of "IP + Robotics + AI" [1] - HAPO-B (02142) entered into an evaluation and licensing agreement with UMOJA BIOPHARMA [1] Financial Data - Hong Kong Exchanges and Clearing (00388) reported a profit attributable to shareholders of HKD 13.419 billion for the first three quarters, a year-on-year increase of 45%, with both revenue and profit reaching record highs [1] - Fubo Group (03738) experienced a total revenue growth of approximately 27% in the third quarter [1] - Goodbaby International (01086) reported a revenue of approximately HKD 6.42 billion for the first three quarters, reflecting a year-on-year decline of 1.1% [1]

Core Viewpoint - The announcement highlights a strategic partnership between Nona Bio and Umoja Biopharma to advance the development of in vivo CAR-T cell products through the integration of their respective platforms [1][2]. Group 1: Partnership Details - Nona Bio has entered into an evaluation and licensing agreement with Umoja Biopharma to combine their HCAb Harbour Mice platform and NonaCarFxTM platform with Umoja's VivoVecTM platform [1]. - The agreement signifies an expansion of the strategic partnership established in September 2024 [1]. - Nona Bio will receive an upfront payment, potential option payments, and milestone payments related to the discovery and development of collaborative projects [1]. Group 2: Company Profiles - Umoja Biopharma is a clinical-stage biotechnology company focused on developing accessible and effective in vivo CAR-T cell therapies for oncology and autoimmune diseases [2]. - The VivoVecTM gene delivery technology enhances the patient's immune system's ability to combat diseases [2]. - Umoja Biopharma operates an advanced lentiviral vector development and manufacturing facility located in Louisville, Colorado, which supports its core technology [2].

Core Insights - Heptares Therapeutics has entered into an evaluation and licensing agreement with Umoja Biopharma to combine their respective platforms for the development of in vivo CAR-T cell products, marking a deepening of their strategic partnership established in September 2024 [1][2] Company Overview - Umoja Biopharma is a clinical-stage biotechnology company focused on developing more accessible and effective in vivo CAR-T cell therapies for oncology and autoimmune diseases [2] - The company's VivoVec gene delivery technology enhances the patient's immune system's ability to combat diseases, supported by an advanced manufacturing facility located in Louisville, Colorado [2] - Umoja Biopharma aims to improve the accessibility and effectiveness of immunotherapies, helping more patients lead better and fuller lives [2]

Group 1 - The core viewpoint of the news is that Nona Bio, a wholly-owned subsidiary of Harbour BioMed, has entered into an evaluation and licensing agreement with Umoja Biopharma to advance the development of multiple in vivo CAR-T cell products [1] - The agreement signifies a deepening of the strategic partnership established between the two companies in September 2024 [1] - Under the terms of the agreement, Nona Bio will receive an upfront payment, potential option payments, and milestone payments related to the discovery and development of collaborative projects [1] Group 2 - Umoja Biopharma is a clinical-stage biotechnology company focused on developing more accessible and effective in vivo CAR-T cell therapies for oncology and autoimmune diseases [2] - The VivoVec in vivo gene delivery technology from Umoja Biopharma enhances the patient's immune system's ability to combat diseases [2] - The company operates an advanced slow virus vector development and manufacturing facility located in Louisville, Colorado, which supports its core technology [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：02142） 自願公告 與UMOJA BIOPHARMA訂立評估與授權協議 本公告由和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願 作出，以告知本公司股東及潛在投資者有關本集團的最新業務更新。 本公司董事會（「董事會」）欣然宣佈，本公司全資子公司諾納生物（蘇州）有限公司 （「諾納生物」）已與Umoja Biopharma, Inc.（「Umoja Biopharma」）訂立評估與授權 協議（「協議」），旨在將諾納生物的HCAb Harbour Mice®平台和NonaCarFxTM平台 與Umoja Biopharma的VivoVecTM平台相結合，共同推進多款體內CAR-T細胞產品 研發。協議標誌著兩家公司於2024年9月建立的戰略合作夥伴關係進一步深化拓 展。 根據協議 ...

Summary of Key Points Core Viewpoint - On November 4, 38 Hong Kong-listed companies conducted share buybacks, totaling 62.68 million shares and an aggregate amount of HKD 294 million [1][2]. Group 1: Buyback Details - China Feihe repurchased 18 million shares for HKD 76.11 million, with a highest price of HKD 4.260 and a lowest price of HKD 4.210, bringing its total buyback amount for the year to HKD 233 million [1][2]. - COSCO Shipping Holdings repurchased 4.5 million shares for HKD 61.70 million, with a highest price of HKD 13.960 and a lowest price of HKD 13.600, accumulating a total buyback amount of HKD 45.30 billion for the year [1][2]. - Pacific Shipping repurchased 10 million shares for HKD 26.09 million, with a highest price of HKD 2.640 and a lowest price of HKD 2.580, totaling HKD 22.91 million in buybacks for the year [1][2]. Group 2: Notable Companies - The largest buyback amount on November 4 was by China Feihe at HKD 76.11 million, followed by COSCO Shipping Holdings at HKD 61.70 million [1][2]. - In terms of share quantity, China Feihe led with 18 million shares repurchased, followed by Pacific Shipping with 10 million shares and Sinopec with 5.15 million shares [1][2]. - Noteworthy is that companies like Fenbi and Taimei Medical Technology conducted their first buybacks of the year on this date [2].